Issuu on Google+

Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Insights

• Targeting unmet needs in the treatment of cancer or hematological malignancies through innovative drug development strategies have witnessed favorable outcomes • Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs - Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival • However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of patients www.researchonglobalmarkets.com


Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Insights (Continued)

• Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM) and Kyprolis (carfilzomib-CFZ) • A similar scenario is expected to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML) • Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature or nascent product or innovator company at a premium

www.researchonglobalmarkets.com


Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Coverage

• Overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory patients • Competition and commercial opportunity in pursuing these therapy areas • Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them

www.researchonglobalmarkets.com


Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Table of Contents

• • • • • • • •

Executive Summary Disease Overview: MDS and AML Current Standard of Care: MDS and AML Unmet Need: AML Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML Late-Stage pipeline Targeting 1st-line Lower Risk MD Key Milestones of Drugs For RRMDS/RRAML in 2014-2015 Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML) • Drivers of M&A/Licensing Deals in MDS/AML

www.researchonglobalmarkets.com


Report: THERAPEUTIC CLASS OVERVIEW TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES Report Details

• • • • • • • • •

Publish date: Feb 22, 2014 Number of slides: 43 Geographic coverage: Global Available format: PDF, CD, Hardcopy Price for Single User License: USD 1,500 Price for Site License: USD 3,003 Price for Global User License: USD 4,503 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com


Therapeutic class overview treating refractory hematological malignancies